Researchers Come Up With New And Promising Strategy To Target Brain Tumours
A potentially promising strategy has been discovered by Massachusetts General Hospital to target brain tumour found in younger adults aged 18 to 45 years.
Led by investigators at the Massachusetts General Hospital, a team of researchers have come up with a way to treat isocitrate dehydrogenase (IDH) genes, which happen to be the most common brain tumours diagnosed in young adults. Their study has been published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR). Prior work by the group had revealed that that IDH mutant gliomas have a metabolic weakness that makes them susceptible to treatments that lower NAD+ levels. They had also found that chemotherapy activates an enzyme that stimulates NAD+ molecules to join together to make PAR (poly ADP-ribose), which is a key DNA damage signal.
Dr Daniel Cahill, a Neurosurgical Oncologist at Mass General and an Associate Professor of Neurosurgery at Harvard Medical School, said, “We found that maximum effectiveness was achieved by combining two agents: temozolomide, the chemotherapy most commonly used to treat patients with IDH mutant gliomas, with a drug that blocks PAR breakdown, known as a PAR glycohydrolase inhibitor.”
Get more news updates on ZEE5.